Protocols

AstraZeneca raises $200M from its latest asset sale; Austin-based Lung Therapeutics raises $14M in venture cash

→  AstraZeneca has sold the rights to its migrane drug, Zomig for $200 million upfront and $102 million in milestones. Germany-based Grünenthal will gain the rights to market and sell the drug outside of Japan. The sale comes as the AstraZeneca is aiming to mount a comeback and refocus on oncology, which it emphasized at ASCO last weekend. In the meantime, the pharma giant has been selling off a string of non-core or disappointing therapies to raise cash.

→  Austin, TX-based Lung Therapeutics successfully completed Series B financing with $14.3. The round was led by Bio Partners and an existing invetsor, UT Horizon Fund. The company is focused on non-surgical interventions for lung injury and disease due to fibrosis.

→  Aimmune celebrated the completion of its commercial manufacturing facility in Clearwater, FL which will be tasked with manufacturing AR101, which is currently in Phase III to treat peanut allergies. Last year, Nestle invested in 7.6 million shares of the Brisbane, CA-based biotech.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Primer Toronto 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->